跳至主要内容
临床试验/NCT02149784
NCT02149784Unknown3 期

Palliative Resection of Asymptomatic Primary Tumor Following Effective Induction Chemotherapy in Colorectal Cancer Patients With Unresectable Distant Metastasis: a Multi-center, Prospective, Randomized Controlled Study

Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 480 人开始时间: 2015年9月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
发起方
入组人数
480
试验地点
1
主要终点
Overall survival

研究概览

简要总结

There is still no perfect treatment suggestion for patients with asymptomatic colorectal cancer with unresectable metastatic disease. Whether patients can benefit from palliative resection of primary tumor or not is still waiting for answer. The investigators hypothesis that asymptomatic metastatic colorectal cancer patients who respond to chemotherapy will benefit from primary tumor resection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18 to 70 years old
  • •both genders
  • •ECOG:0-2 score
  • •Pathological confirmed colon cancer or rectal cancer with at least 12 cm far away from anal verge
  • •CT,MRI,or PET-CT confirmed metastasis
  • •MDT confirmed unresectable metastasis lesion
  • •No evidence of obstruction, bleeding, perforation
  • •WBC≥4.0×109/L,Neu ≥2.0×109/L,PLT≥100×109/L
  • •No contraindication for chemotherapy
  • •No evidence of other malignant tumor
  • •Expected survival time > 6 months

排除标准

  • •mCRC patients who did not respond to first line chemotherapy
  • •Require surgical intervention during the primary tumor-related symptoms
  • •Obvious coagulopathy
  • •Severe heart, liver, kidney damage or other serious uncontrolled medical illness or acute infection, cachexia
  • •Severe organ damage after chemotherapy, surgery or unable to continue to systemic chemotherapy
  • •Pregnant or lactating women or women of childbearing age who refuse to accept contraception.
  • •Nearly three months participated in clinical trials of other persons.
  • •Mental abnormalities

研究组 & 干预措施

Surgical treatment group

Experimental

Unresectable mCRC patients who respond to chemotherapy will receive surgical resection of primary tumor.

干预措施: Surgical resection of primary tumor (Procedure)

Chemotherapy group

No Intervention

Unresectable mCRC patients who were respond to chemotherapy will continue with chemotherapy.

结局指标

主要结局

Overall survival

时间窗: 3 years

次要结局

  • Number of Participants with Adverse Events both in surgery group and chemotherapy group(2 years)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gong Chen

Sun Yat-Sen University Cancer Center

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma PeritoneiGastrointestinal Neoplasms
NCT01946854M.D. Anderson Cancer Center30
尚未招募
不适用
Refractory advanced colorectal cancer in the treatment with integrated traditional Chinese and western medicine: a multi-center clinical studycolorectal cancer
ITMCTR2200006741onghua Hospital, Shanghai University of Traditional Chinese Medicine
进行中(未招募)
1 期
A randomized phase 3 study of treatment strategies for patients with colon cancer with metastases only in the liver, which is (at this moment) not eligible for surgical treatment. A study of the Dutch Colorectal Cancer Group (DCCG).Colorectal cancer with initially irresectable liver-only metastases
EUCTR2013-005435-24-NLDutch Colorectal Cancer Group584
招募中
3 期
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases. CAIRO5 a randomized phase 3 study of the Dutch Colorectal Cancer Group (DCCG)10017991Bowel CancerColorectal cancer
NL-OMON54605Dutch Colorectal Cancer Group584
进行中(未招募)
1 期
Alternating chemotherapy plus cetuximab to allow resection of metastases from a colorectal cancer that is wild-type KRAS and BRAF - a randomised phase II trial - Nordic 7.6MedDRA version: 14.1 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic colorectal cancer with wild-type KRAS and BRAFMedDRA version: 14.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-004188-65-SEOdense University Hospital180